Protocol Ledger

NCT03659916 · Phase III · COMPLETED

Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC

Interventional Phase III clinical trial protocol NCT03659916 sponsored by Albireo, an Ipsen Company in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-09-28 Enrollment: 116 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03659916
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)116 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03659916
Protocol FieldVerified Registry Value
NCT IdentifierNCT03659916
Consolidated Lead SponsorAlbireo, an Ipsen Company
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment116 participants (ACTUAL)
Registered Start Date2018-09-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI